Kyntra Bio (KYNB) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Quoin Pharmaceuticals (QNRX) has outperformed Kyntra Bio (KYNB) over the past year, losing 44.4% versus a loss of 47.7%. Over five years, KYNB leads with a -97.8% price change compared with -100.0% for QNRX. Kyntra Bio is the larger company by market cap ($24.1 million vs $21.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | QNRX |
|---|---|---|
| Share price | $5.96 | $4.55 |
| Market cap | $24.13M | $21.86M |
| 1-day change | -1.32% | -3.19% |
| YTD return | -32.12% | -68.47% |
| 1-year return | -47.72% | -44.44% |
| 5-year return | -97.84% | -99.99% |
| EPS (TTM) | $-7.64 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.65 | $41.80 |
| 52-week low | $5.62 | $3.25 |
| Distance from 52-week high | -48.84% | -89.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +565.60% | +379.78% |
| Average volume | 18.29K | 541.11K |
| Shares outstanding | 4.05M | 4.80M |
| Employees | 34 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Healthcare · Biotechnology · 34 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Healthcare · Biotechnology · 4 employees
KYNB vs QNRX FAQ
Which is bigger, Kyntra Bio or Quoin Pharmaceuticals?
Kyntra Bio (KYNB) is larger, with a market capitalization of $24.13M compared with $21.86M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, KYNB or QNRX?
QNRX returned -44.44% over the past 12 months, compared with -47.72% for KYNB (price return, excluding dividends). Past performance does not predict future results.
Are Kyntra Bio and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.